Skip to main content

Sulfonylurea

08-31-2023 | Type 2 diabetes | News

Pragmatic trial suggests best cardioprotective agents for type 2 diabetes

SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

04-24-2023 | Sulfonylureas | News

Sulfonylureas ‘unlikely’ to increase CV, mortality risk in real-world use

Findings from a Scottish national cohort study show that the use of sulfonylureas as second-line glucose-lowering therapy is not associated with elevated cardiovascular risk or all-cause mortality.

10-14-2022 | Dementia | News

Glitazone use linked to reduced dementia risk in type 2 diabetes

People aged 60 years or older receiving thiazolidinedione monotherapy for type 2 diabetes may have a lower risk for dementia than those taking metformin monotherapy, an observational study suggests.

09-22-2022 | EASD 2022 | Conference coverage | News

Model could predict severe hypoglycemia risk in people with type 2 diabetes

A number of factors are associated with severe hypoglycemia risk in people with type 2 diabetes treated with insulin or sulfonylureas, suggests research reported at the 58th EASD Annual Meeting in Stockholm, Sweden.

Doctor holds in his hands the kidney concept

09-01-2022 | Metformin | News

People with type 2 diabetes and CKD missing out on renoprotective drugs

People with type 2 diabetes and chronic kidney disease are substantially less likely to initiate SGLT2 inhibitors than those with normal kidney function, despite their proven renoprotective benefits, research shows.

Heart failure concept

12-17-2021 | Heart failure | News

Metformin, but not sulfonylurea, may reduce poor outcome risk post HHF

Initiating metformin following hospitalization for heart failure may reduce the risk for death or further HHF in older people with comorbid diabetes, but only if they have a preserved ejection fraction, study findings indicate.

11-11-2021 | Sulfonylureas | News

Sulfonylurea, insulin deintensification lags behind recommendations

Fewer than half of older adults receiving a sulfonylurea and/or insulin have their treatment deintensified after an emergency department visit or hospitalization for hypoglycemia, despite guidelines recommending this practice, US research shows.

10-13-2021 | Liraglutide (T2DM) | News

Liraglutide add-on may offer better control than OADs in type 2 diabetes

The addition of liraglutide rather than extra oral antidiabetic drugs may offer more sustained glycemic control for people with type 2 diabetes who have inadequate control with metformin, suggest findings of the international LIRA-PRIME study.